Novartis’ pelacarsen fails to meet primary endpoint in Lp(a)HORIZON trial

Novartis has reported that the Phase III Lp(a)HORIZON trial of pelacarsen failed to meet its primary endpoint in patients with elevated Lp(a) and established CVD. The trial assessed four-point major adverse cardiovascular events in an overall population with Lp(a) of 70mg/dL or above. The trial enrolled 8,323 patients with elevated Lp(a) and established cardiovascular disease. Credit: sasirin pamai / Shutterstock.com. Novartis has reported that the Phase III Lp(a)HORIZON trial of pelacarsen failed to meet its primary endpoint in patients with elevated Lp(a) and established cardiovascular disease (CVD). The study did not show a reduction in the risk of cardiovascular events…

Source: Clinical Trials Arena